Trials / Not Yet Recruiting
Not Yet RecruitingNCT07516093
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
A Phase 3, Randomized, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 620 (estimated)
- Sponsor
- Nurix Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate the efficacy and safety of NX-5948 (bexobrutideg) versus pirtobrutinib in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who are relapsed or refractory to prior covalent Bruton tyrosine kinase inhibitor (cBTKi) treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NX-5948 | Administered orally once daily |
| DRUG | Pirtobrutinib | Administered orally once daily per prescribing information |
Timeline
- Start date
- 2026-06-01
- Primary completion
- 2029-10-01
- Completion
- 2032-06-01
- First posted
- 2026-04-07
- Last updated
- 2026-04-08
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07516093. Inclusion in this directory is not an endorsement.